Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CHEK2 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase Chk2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CHEK2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
BUB1B Biologics Sequence Review Report 2026: Mitotic checkpoint serine/threonine-protein kinase BUB1 beta Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of BUB1B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
BUB1 Biologics Sequence Review Report 2026: Mitotic checkpoint serine/threonine-protein kinase BUB1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of BUB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CHEK1 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase Chk1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CHEK1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLIN3 Biologics Sequence Review Report 2026: Perilipin-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PLIN3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GFRA3 Biologics Sequence Review Report 2026: GDNF family receptor alpha-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GFRA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GSDME Biologics Sequence Review Report 2026: Gasdermin-E Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GSDME protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GRIN3B Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 3B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRIN3B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MED14 Biologics Sequence Review Report 2026: Mediator of RNA polymerase II transcription subunit 14 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of MED14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNA2 Biologics Sequence Review Report 2026: Ephrin-A2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of EFNA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
TYROBP Biologics Sequence Review Report 2026: TYRO protein tyrosine kinase-binding protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TYROBP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CYTH3 Biologics Sequence Review Report 2026: Cytohesin-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CYTH3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
586
587
588
589
590
>>
1905
>